Center for Esophageal Diseases and Swallowing, Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Inform Diagnostics, Irving, Texas; Dallas Veterans Affairs Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2102-2111. doi: 10.1016/j.cgh.2020.08.013. Epub 2020 Aug 12.
BACKGROUND & AIMS: Mast cells are believed to contribute to the development of eosinophilic gastrointestinal disorders (EGIDs). We quantified mast cells and eosinophils in biopsy specimens from patients with EGIDs and without known esophageal or gastrointestinal disease to investigate associations between these cell types and EGID and its features. METHODS: We conducted a retrospective study of patients with EGID (n = 52) and of children and adults who underwent upper endoscopy and were found to have no evidence of gastrointestinal or systemic conditions (n = 123). We re-reviewed archived gastric and duodenal biopsy specimens to quantify mast cells (by tryptase immunohistochemistry) and eosinophils. We calculated the specificity of cell count thresholds for identification of patients with EGIDs and evaluated the correlation between mast cell and eosinophil counts and clinical and endoscopic features. RESULTS: In the gastric biopsy specimens from patients without esophageal or gastrointestinal diseases, the mean mast cell count was 18.1 ± 7.2 cells per high-power field (hpf), and the peak mast cell count was 21.9 ± 8.2 cells/hpf. In the duodenal biopsy specimens from patients without esophageal or gastrointestinal diseases, the mean mast cell count was 23.6 ± 8.1 cells/hpf and the peak mast cell count was 28.1 ± 9.3 cells/hpf. The mean and peak eosinophil counts in gastric biopsy specimens from patients without disease were 3.8 ± 3.6 eosinophils/hpf and 5.8 ± 5.0 eosinophils/hpf; the mean and peak eosinophil counts in duodenal biopsy specimens were 14.6 ± 8.9 eosinophils/hpf and 19.5 ± 11.0 eosinophils/hpf. A mean count of 20 eosinophils/hpf in gastric biopsy specimens or 30 eosinophils/hpf in duodenal biopsy specimens identified patients with EGIDs with high specificity. Gastric and duodenal biopsy specimens from patients with EGIDs had significant increases in mean mast cell counts compared with biopsy specimens from patients without EGIDs. There was a correlation between mean mast cell and eosinophil counts in duodenal biopsy specimens (R = 0.47; P = .01). The mean mast cell and eosinophil counts did not correlate with symptoms or endoscopic features of EGIDs. CONCLUSIONS: We identified thresholds for each cell type that identified patients with EGIDs with 100% specificity. The increased numbers of mast cells and eosinophils in gastric and duodenal tissues from patients with EGIDs supports the concept that these cell types are involved in pathogenesis. However, cell counts are not associated with symptoms or endoscopic features of EGIDs.
背景与目的: 肥大细胞被认为有助于嗜酸性粒细胞性胃肠道疾病(EGIDs)的发展。我们定量分析了 EGIDs 患者和无已知食管或胃肠道疾病患者的活检标本中的肥大细胞和嗜酸性粒细胞,以研究这些细胞类型与 EGID 及其特征之间的关系。 方法: 我们对 52 例 EGID 患者(n=52)和 123 例接受上消化道内镜检查且无胃肠道或全身疾病证据的儿童和成人进行了回顾性研究。我们重新审查了存档的胃和十二指肠活检标本,以定量检测肥大细胞(通过 tryptase 免疫组织化学)和嗜酸性粒细胞。我们计算了细胞计数阈值用于识别 EGID 患者的特异性,并评估了肥大细胞和嗜酸性粒细胞计数与临床和内镜特征之间的相关性。 结果: 在无食管或胃肠道疾病患者的胃活检标本中,平均肥大细胞计数为 18.1±7.2 个/高倍视野(hpf),最高肥大细胞计数为 21.9±8.2 个/hpf。在无食管或胃肠道疾病患者的十二指肠活检标本中,平均肥大细胞计数为 23.6±8.1 个/hpf,最高肥大细胞计数为 28.1±9.3 个/hpf。无疾病患者胃活检标本的平均和最高嗜酸性粒细胞计数分别为 3.8±3.6 个/嗜酸性粒细胞/hpf 和 5.8±5.0 个/嗜酸性粒细胞/hpf;十二指肠活检标本的平均和最高嗜酸性粒细胞计数分别为 14.6±8.9 个/嗜酸性粒细胞/hpf 和 19.5±11.0 个/嗜酸性粒细胞/hpf。胃活检标本中平均 20 个嗜酸性粒细胞/hpf 或十二指肠活检标本中平均 30 个嗜酸性粒细胞/hpf 可识别出 EGID 患者,特异性为 100%。与无 EGID 患者的活检标本相比,EGID 患者的胃和十二指肠活检标本中平均肥大细胞计数显著增加。十二指肠活检标本中平均肥大细胞和嗜酸性粒细胞计数之间存在相关性(R=0.47;P=0.01)。平均肥大细胞和嗜酸性粒细胞计数与 EGIDs 的症状或内镜特征无关。 结论: 我们确定了每个细胞类型的阈值,可 100%特异性识别 EGID 患者。EGIDs 患者胃和十二指肠组织中肥大细胞和嗜酸性粒细胞数量的增加支持这些细胞类型参与发病机制的概念。然而,细胞计数与 EGIDs 的症状或内镜特征无关。
Clin Gastroenterol Hepatol. 2021-10
Clin Gastroenterol Hepatol. 2022-3
J Allergy Clin Immunol. 2023-4
J Pediatr Gastroenterol Nutr. 2021-2-1
Clin Gastroenterol Hepatol. 2012-1-28
Gastroenterol Hepatol (N Y). 2025-8
Clin Transl Gastroenterol. 2024-7-1
Immunol Allergy Clin North Am. 2024-5
J Allergy Clin Immunol. 2024-6
Curr Allergy Asthma Rep. 2024-5
J Neurogastroenterol Motil. 2018-10-1
Virchows Arch. 2018-7-10
Lancet Gastroenterol Hepatol. 2018-3-7
Gastroenterology. 2018-1